Medicines For Malaria Venture Partners With Africa CDC
By Samuel Ouma
Medicines for Malaria Venture (MMV) and the Africa Centres for Disease Control and Prevention (Africa CDC) ON Thursday signed a Memorandum of Understanding (MoU) to strengthen African manufacturing of malaria medicines.
The MoU deal was signed during the 2nd International Conference on Public Health in Africa (CPHIA 2022) in Kigali, Rwanda.
The goal of the MoU is to optimize the use and health benefits of currently available products across the continent by enhancing supply security and facilitating fair access to high-quality, licensed antimalarials.
“MMV and Africa CDC share a common goal of delivering quality-assured essential medicines produced in Africa,” said Pierre Hugo, MMV’s Senior Director of Market Dynamics and Global Partnerships. “We believe that targeted investments and collaboration with select manufacturers will create opportunities to expand access to quality antimalarials throughout both the public and private sectors.”
The MoU further outlines how MMV and Africa CDC will work with partners to ensure funding and procurement of locally manufactured quality-assured medicines.
“Africa is capable of manufacturing its own medicines,” said Dr. Nicaise Ndembi, Africa CDC’s Senior Science Advisor. “The partnership between Africa CDC and MMV will increase local medicine manufacturing and focus on establishing several regional hubs to manufacture Active Pharmaceutical Ingredients (API) and Finished Pharmaceutical Products (FPP).”